Literature DB >> 16878127

Gene targeting in vivo by adeno-associated virus vectors.

Daniel G Miller1, Pei-Rong Wang, Lisa M Petek, Roli K Hirata, Mark S Sands, David W Russell.   

Abstract

Therapeutic gene delivery typically involves the addition of a transgene expression cassette to mutant cells. This approach is complicated by transgene silencing, aberrant transcriptional regulation and insertional mutagenesis. An alternative strategy is to correct mutations through homologous recombination, allowing for normal regulation of gene expression from the endogenous locus. Adeno-associated virus (AAV) vectors containing single-stranded DNA efficiently transduce cells in vivo and have been shown to target homologous chromosomal sequences in cultured cells. To determine whether AAV-mediated gene targeting can occur in vivo, we developed a mouse model that contains a mutant, nuclear-localized lacZ gene inserted at the ubiquitously expressed ROSA26 locus. Foci of beta-galactosidase-positive hepatocytes were observed in these mice after injection with an AAV vector containing a lacZ gene fragment, and precise correction of the 4-bp deletion was demonstrated by gene sequencing. We also used AAV gene-targeting vectors to correct the naturally occurring GusB gene mutation responsible for murine mucopolysaccharidosis type VII.

Entities:  

Mesh:

Year:  2006        PMID: 16878127     DOI: 10.1038/nbt1231

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  49 in total

Review 1.  Gene therapy for mucopolysaccharidosis.

Authors:  Katherine P Ponder; Mark E Haskins
Journal:  Expert Opin Biol Ther       Date:  2007-09       Impact factor: 4.388

2.  Targeted genetic modification of cell lines for recombinant protein production.

Authors:  Niall Barron; Olga Piskareva; Mohan Muniyappa
Journal:  Cytotechnology       Date:  2007-02-28       Impact factor: 2.058

Review 3.  Viral vectors: from virology to transgene expression.

Authors:  D Bouard; D Alazard-Dany; F-L Cosset
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

Review 4.  Recombinant adeno-associated virus transduction and integration.

Authors:  Brian R Schultz; Jeffrey S Chamberlain
Journal:  Mol Ther       Date:  2008-05-20       Impact factor: 11.454

Review 5.  Viral vectors for therapy of neurologic diseases.

Authors:  Sourav R Choudhury; Eloise Hudry; Casey A Maguire; Miguel Sena-Esteves; Xandra O Breakefield; Paola Grandi
Journal:  Neuropharmacology       Date:  2016-02-21       Impact factor: 5.250

6.  Hitting the target without pulling the trigger.

Authors:  Thierry VandenDriessche; Marinee K Chuah
Journal:  Mol Ther       Date:  2015-01       Impact factor: 11.454

7.  Future of rAAV Gene Therapy: Platform for RNAi, Gene Editing, and Beyond.

Authors:  Paul N Valdmanis; Mark A Kay
Journal:  Hum Gene Ther       Date:  2017-01-10       Impact factor: 5.695

8.  rAAV-mediated tumorigenesis: still unresolved after an AAV assault.

Authors:  Paul N Valdmanis; Leszek Lisowski; Mark A Kay
Journal:  Mol Ther       Date:  2012-11       Impact factor: 11.454

9.  An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation.

Authors:  Byoung Y Ryu; Marguerite V Evans-Galea; John T Gray; David M Bodine; Derek A Persons; Arthur W Nienhuis
Journal:  Blood       Date:  2007-11-08       Impact factor: 22.113

10.  A comparison of synthetic oligodeoxynucleotides, DNA fragments and AAV-1 for targeted episomal and chromosomal gene repair.

Authors:  Xavier Leclerc; Olivier Danos; Daniel Scherman; Antoine Kichler
Journal:  BMC Biotechnol       Date:  2009-04-20       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.